pirinixic acid has been researched along with Inflammation in 22 studies
pirinixic acid: structure
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inflammation is a local immune response to 'foreign' molecules, infection and injury." | 5.29 | The PPARalpha-leukotriene B4 pathway to inflammation control. ( Devchand, PR; Gonzalez, FJ; Keller, H; Peters, JM; Vazquez, M; Wahli, W, 1996) |
| "in inflammation, neurodegeneration and cancer seem very promising." | 2.55 | Therapeutic applications of the versatile fatty acid mimetic WY14643. ( Merk, D; Pollinger, J, 2017) |
| "Depression is a common disease that afflicts one in six people at some points in life." | 1.46 | WY-14643, a selective agonist of peroxisome proliferator-activated receptor-α, ameliorates lipopolysaccharide-induced depressive-like behaviors by preventing neuroinflammation and oxido-nitrosative stress in mice. ( Chen, Z; Gong, Y; Hu, W; Huang, C; Wang, P; Yang, R; Zhang, W, 2017) |
| "Here, we expanded MSs from human breast cancer and normal mammary gland tissues, as well from tumorigenic (MCF7) and non-tumorigenic (MCF10) breast cell lines." | 1.38 | Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. ( Avenia, N; Bonafé, M; Ceccarelli, C; De Carolis, S; Guarnieri, T; Orlandi, M; Papi, A; Sanguinetti, A; Santini, D; Sidoni, A; Storci, G; Taffurelli, M, 2012) |
| "Indomethacin was less effective, though tissue prostaglandin E2 but not leukotriene B4 levels were reduced." | 1.33 | The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. ( Andrews, G; Colville-Nash, P; Freemantle, C; Lam, C; Papworth, J; Willis, D; Willoughby, D, 2005) |
| "Moreover, Wy-14,643 treatment reduced inflammation and the expression of macrophage-specific genes in white adipose tissue (WAT)." | 1.33 | Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. ( Hada, Y; Ito, Y; Kadowaki, T; Maki, T; Takekawa, S; Tsuchida, A; Yamauchi, T, 2005) |
| "Fibrinogen is a coagulation factor and an acute phase reactant up-regulated by inflammatory cytokines, such as interleukin 6 (IL-6)." | 1.31 | Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. ( Dubois, G; Fruchart, JC; Gervois, P; Kleemann, R; Kockx, M; Kooistra, T; Kosykh, V; Laine, B; Staels, B; Vu-Dac, N, 2001) |
| "Inflammation is a local immune response to 'foreign' molecules, infection and injury." | 1.29 | The PPARalpha-leukotriene B4 pathway to inflammation control. ( Devchand, PR; Gonzalez, FJ; Keller, H; Peters, JM; Vazquez, M; Wahli, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Werz, O | 2 |
| Greiner, C | 2 |
| Koeberle, A | 2 |
| Hoernig, C | 1 |
| George, S | 1 |
| Popescu, L | 1 |
| Syha, I | 1 |
| Schubert-Zsilavecz, M | 2 |
| Steinhilber, D | 1 |
| Zettl, H | 1 |
| Wurglics, M | 1 |
| Kim, SO | 1 |
| Han, Y | 2 |
| Ahn, S | 1 |
| An, S | 1 |
| Shin, JC | 1 |
| Choi, H | 1 |
| Kim, HJ | 1 |
| Park, NH | 1 |
| Kim, YJ | 1 |
| Jin, SH | 1 |
| Rho, HS | 1 |
| Noh, M | 1 |
| Jiao, M | 1 |
| Ren, F | 1 |
| Zhou, L | 1 |
| Zhang, X | 2 |
| Zhang, L | 1 |
| Wen, T | 1 |
| Wei, L | 1 |
| Wang, X | 1 |
| Shi, H | 1 |
| Bai, L | 1 |
| Zheng, S | 1 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Zhao, C | 1 |
| Duan, Z | 1 |
| Pollinger, J | 1 |
| Merk, D | 1 |
| Yang, R | 1 |
| Wang, P | 1 |
| Chen, Z | 1 |
| Hu, W | 1 |
| Gong, Y | 1 |
| Zhang, W | 1 |
| Huang, C | 1 |
| Schaefer, MB | 1 |
| Pose, A | 1 |
| Ott, J | 1 |
| Hecker, M | 1 |
| Behnk, A | 1 |
| Schulz, R | 1 |
| Weissmann, N | 1 |
| Günther, A | 1 |
| Seeger, W | 1 |
| Mayer, K | 1 |
| Clockaerts, S | 1 |
| Bastiaansen-Jenniskens, YM | 1 |
| Feijt, C | 1 |
| Verhaar, JA | 1 |
| Somville, J | 1 |
| De Clerck, LS | 1 |
| Van Osch, GJ | 1 |
| Papi, A | 1 |
| Guarnieri, T | 1 |
| Storci, G | 1 |
| Santini, D | 1 |
| Ceccarelli, C | 1 |
| Taffurelli, M | 1 |
| De Carolis, S | 1 |
| Avenia, N | 1 |
| Sanguinetti, A | 1 |
| Sidoni, A | 1 |
| Orlandi, M | 1 |
| Bonafé, M | 1 |
| Mogilenko, DA | 1 |
| Kudriavtsev, IV | 1 |
| Shavva, VS | 1 |
| Dizhe, EB | 1 |
| Vilenskaya, EG | 1 |
| Efremov, AM | 1 |
| Perevozchikov, AP | 1 |
| Orlov, SV | 1 |
| Cheng, S | 1 |
| Afif, H | 1 |
| Martel-Pelletier, J | 1 |
| Pelletier, JP | 1 |
| Li, X | 1 |
| Farrajota, K | 1 |
| Lavigne, M | 1 |
| Fahmi, H | 1 |
| Teissier, E | 1 |
| Nohara, A | 1 |
| Chinetti, G | 3 |
| Paumelle, R | 1 |
| Cariou, B | 1 |
| Fruchart, JC | 4 |
| Brandes, RP | 1 |
| Shah, A | 1 |
| Staels, B | 4 |
| Colville-Nash, P | 1 |
| Willis, D | 1 |
| Papworth, J | 1 |
| Freemantle, C | 1 |
| Lam, C | 1 |
| Andrews, G | 1 |
| Willoughby, D | 1 |
| Tsuchida, A | 1 |
| Yamauchi, T | 1 |
| Takekawa, S | 1 |
| Hada, Y | 1 |
| Ito, Y | 1 |
| Maki, T | 1 |
| Kadowaki, T | 1 |
| Suardíaz, M | 1 |
| Estivill-Torrús, G | 1 |
| Goicoechea, C | 1 |
| Bilbao, A | 1 |
| Rodríguez de Fonseca, F | 1 |
| Babaev, VR | 1 |
| Ishiguro, H | 1 |
| Ding, L | 1 |
| Yancey, PG | 1 |
| Dove, DE | 1 |
| Kovacs, WJ | 1 |
| Semenkovich, CF | 1 |
| Fazio, S | 1 |
| Linton, MF | 1 |
| Devchand, PR | 1 |
| Keller, H | 1 |
| Peters, JM | 1 |
| Vazquez, M | 1 |
| Gonzalez, FJ | 1 |
| Wahli, W | 1 |
| Koenig, W | 1 |
| Habib, A | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Torra, IP | 2 |
| Delerive, P | 2 |
| Fadel, A | 1 |
| Najib, J | 2 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Griglio, S | 1 |
| Antonucci, M | 1 |
| Majd, Z | 1 |
| Chapman, J | 1 |
| Gervois, P | 1 |
| Vu-Dac, N | 1 |
| Kleemann, R | 1 |
| Kockx, M | 1 |
| Dubois, G | 1 |
| Laine, B | 1 |
| Kosykh, V | 1 |
| Kooistra, T | 1 |
| Taylor, BK | 1 |
| Dadia, N | 1 |
| Yang, CB | 1 |
| Krishnan, S | 1 |
| Badr, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| A Pilot Study to Assess the Effects of Regulating Urine pH Levels for Alleviating Chronic Joint Pain[NCT01421160] | Phase 1 | 0 participants (Actual) | Interventional | 2011-07-31 | Withdrawn (stopped due to PI left the institution prior to any data being collected) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
2 reviews available for pirinixic acid and Inflammation
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Therapeutic applications of the versatile fatty acid mimetic WY14643.
Topics: Animals; Anticholesteremic Agents; Drug Design; Fatty Acids; Humans; Inflammation; Molecular Targete | 2017 |
20 other studies available for pirinixic acid and Inflammation
| Article | Year |
|---|---|
Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.
Topics: Aminoquinolines; Cells, Cultured; Esterification; Humans; Hypersensitivity; Inflammation; Leukocytes | 2008 |
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
Topics: Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Drug | 2008 |
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
Topics: Adipogenesis; Adiponectin; Cinnamates; Dinoprostone; Humans; Inflammation; Keratinocytes; Matrix Met | 2018 |
Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.
Topics: Acute Disease; Adenine; Adult; Animals; Autophagy; Autophagy-Related Protein 7; Cells, Cultured; Che | 2014 |
WY-14643, a selective agonist of peroxisome proliferator-activated receptor-α, ameliorates lipopolysaccharide-induced depressive-like behaviors by preventing neuroinflammation and oxido-nitrosative stress in mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Hindlimb Suspension; Inflammation | 2017 |
Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury.
Topics: Acute Lung Injury; Animals; Capillaries; Disease Models, Animal; Endotoxins; Inflammation; Lipopolys | 2008 |
Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage.
Topics: Aggrecans; Cartilage, Articular; Cells, Cultured; Collagen Type II; Dinoprostone; Glycosaminoglycans | 2011 |
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Inflammation; Interleukin-6; Neop | 2012 |
Peroxisome proliferator-activated receptor α positively regulates complement C3 expression but inhibits tumor necrosis factor α-mediated activation of C3 gene in mammalian hepatic-derived cells.
Topics: Animals; Complement C3; Gene Expression Regulation; Gene Knockdown Techniques; Hep G2 Cells; Hepatoc | 2013 |
Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1.
Topics: Amino Acid Motifs; Anilides; Binding Sites; Blotting, Western; Cell Division; Cell Nucleus; Chromans | 2004 |
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.
Topics: Animals; Enzyme Activation; Glutathione; Humans; Inflammation; Lipoproteins, LDL; Macrophages; Macro | 2004 |
The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Dinoprostone; | 2005 |
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Topics: Animals; Blood Glucose; Epididymis; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation; Insul | 2005 |
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Topics: Analgesics; Animals; Anticholesteremic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine | 2007 |
Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Topics: Animals; Aortic Diseases; Atherosclerosis; Biological Transport; Bone Marrow Transplantation; Butyra | 2007 |
The PPARalpha-leukotriene B4 pathway to inflammation control.
Topics: Adaptation, Physiological; Animals; Arachidonic Acid; Cells, Cultured; Chloramphenicol O-Acetyltrans | 1996 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.
Topics: Apoptosis; Arteriosclerosis; Caspase 3; Caspases; Cell Differentiation; Humans; Immunohistochemistry | 1998 |
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.
Topics: Blotting, Northern; Blotting, Western; CCAAT-Enhancer-Binding Protein-alpha; Cell Line; Dose-Respons | 2001 |
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia.
Topics: Animals; Carrageenan; Disease Models, Animal; Edema; Hyperalgesia; Inflammation; Ligands; Male; Pero | 2002 |